Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.